Anzeige
Meldung des Tages: Der 9,5 Mio. € Kupferfehler des Marktes – Und solche Fehler korrigieren sich schnell

Phio Pharmaceuticals News

Aktie
WKN:  A40GMU ISIN:  US71880W5013 US-Symbol:  PHIO Branche:  Biotechnologie Land:  USA
1,18 $
-0,01 $
-0,84%
1,0200 € 05.03.26
Depot/Watchlist
Marktkapitalisierung *
5,26 Mio. €
Streubesitz
73,98%
KGV
-1,98
Index-Zuordnung
-

Phio Pharmaceuticals News

23.02.26 - EQS
EQS-News: Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company
EQS-News: B2i Digital, Inc. / Key word(s): Financial Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company 23.02.2026 / 15:49 CET/CEST The issuer is solely ...
06.12.23 - PR Newswire
Thinking about buying stock in Brainstorm Cell Therapeutics, Clearmind Medicine, Phio Pharmaceuticals, Aspen Aerogels, or Immunoprecise Antibodies?
Thinking about buying stock in Brainstorm Cell Therapeutics, Clearmind Medicine, Phio Pharmaceuticals, Aspen Aerogels, or Immunoprecise Antibodies? PR Newswire
13.10.23 - PR Newswire
Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals?
Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals? PR Newswire
02.06.23 - PR Newswire
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
31.05.23 - PR Newswire
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
24.05.23 - PR Newswire
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute ...
18.05.23 - PR Newswire
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells PR Newswire
16.05.23 - PR Newswire
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas PR Newswire
11.05.23 - PR Newswire
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR Newswire
20.04.23 - PR Newswire
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
18.04.23 - PR Newswire
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-​the-Market Under Nasdaq Rules PR Newswire
18.04.23 - PR Newswire
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-​Enhanced in vivo Anti-​Tumor Efficacy of PD-1/CTLA-4 Dual-​Targeting INTASYL PR Newswire
17.04.23 - PR Newswire
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-​Tumor Immunity PR Newswire
22.03.23 - PR Newswire
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update PR Newswire
13.02.23 - PR Newswire
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire
10.02.23 - PR Newswire
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification PR Newswire
25.01.23 - PR Newswire
Phio Pharmaceuticals Announces Reverse Stock Split
Phio Pharmaceuticals Announces Reverse Stock Split PR Newswire
06.01.23 - PR Newswire
Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco
Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco PR Newswire
06.01.23 - PR Newswire
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors PR Newswire
21.12.22 - PR Newswire
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma PR Newswire

Newssuche

Videos

newspaper
04.03.26 +13,80%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »